Public call for individual patient data on treatment of multidrug- and rifampicin-resistant TB.

The new WHO Preferred Product Characteristics for New Tuberculosis Vaccines draft document is now available online for public review and comment.

07 February 2018, Geneva - The World Health Organization (WHO) would like to invite all civil society representatives and partners to participate in a special webinar on the WHO guideline development process, with a focus on guidelines for the management of multidrug-resistant TB (MDR-TB). The webinar will be held on 27 February from 15:00H-17:00H CET.

WHO Executive Board adopts resolution on upcoming United Nations General Assembly High-Level Meeting on TB.

24 January 2018, Geneva - Advances in mobile technologies, network coverage and internet access have transformed the way we interact with each other. These developments create novel possibilities to improve patient care, and reduce patient and health system costs. They have the potential to advance the notion of patient-centred care, bringing it within reach of many low resource settings.

WHO leadership meets with TB civil society to strengthen engagement in accelerating the End TB response.

The World Health Organization issues a position statement on the use of delamanid for multidrug-resistant TB following an expedited review of phase III clinical trial results.

The dispersible child-friendly TB fixed-dose combinations (FDCs) produced by Macleods Pharmaceuticals Ltd. have both received WHO prequalification (PQ):

The WHO Regional Office for Europe is seeking input on a United Nations (UN) common position paper on ending tuberculosis (TB), HIV and viral hepatitis through intersectoral collaboration, drafted in collaboration with sister UN agencies. The consultation survey will remain available until 11 January 2018 and can be accessed here.

Geneva, 13 December 2017 – On the occasion of the Universal Health Coverage (UHC) Day, dedicated to ensuring that everyone in the world can access the health services they need without suffering financial hardship, the side event “Reaching the underserved and vulnerable: TB responses as a pathway to UHC” took place yesterday in Tokyo in the framework of the UHC Forum 2017.